查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1741139

药物和基因递送设备市场：按产品、非处方药和地区划分

Drug and Gene Delivery Devices Market, By Product, By Commercialized Drugs, and By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 155 Pages | 商品交期: 2-3个工作天内

价格
简介目录

药物和基因输送设备市场规模预计在 2025 年达到 210,800 美元，预计到 2032 年将达到 454,500 美元，2025 年至 2032 年的复合年增长率为 11.6%。

报告范围 报告详细信息
基准年 2024 2025年的市场规模 210,800美元
效能数据 2020-2024 预测期 2025-2032
预测期间：2025年至2032年的复合年增长率 11.60% 2032年价值预测 454,500美元

药物和基因递送装置领域涉及药物、基因和基因产物的开发和递送，这些药物、基因和基因产物最终会改变细胞、组织和生物体中的蛋白质表现和/或功能。药物递送装置是透过特定给药途径递送药物的工具。而基因递送则是将外来遗传物质（例如DNA和RNA）引入宿主细胞的过程。

市场动态

感染疾病、心血管疾病、癌症和糖尿病等慢性疾病负担的增加、对药物和基因递送装置的需求的增加、对细胞和基因治疗的资金的增加以及对基因治疗的核准的增加是预计在预测期内促进全球药物和基因递送装置市场增长的关键因素。

例如，2022年11月，Imunon, Inc. 与 Acuitas Therapeutics 达成协议，评估 Imunon 的 PLACCINE 核酸疫苗构建体与 Acuitas 专有脂质递送技术的结合效果。根据协议，Imunon 将使用以各种 Acuitas LNP 製剂配製的载体构建体，以评估小鼠模型中的基因表现和免疫抗原性。

本研究的主要特点

  • 本报告对全球药物和基因输送装置市场进行了详细分析，并提供了预测期 2025-2032（以 2024 年为基准年）的市场规模和年复合成长率（CAGR%）。
  • 它还强调了各个领域的潜在商机，并说明了该市场的有吸引力的投资提案矩阵。
  • 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。
  • 全球药物和基因输送装置市场的主要企业会根据以下参数进行分析，例如公司亮点、产品系列、关键亮点、财务表现和策略。
  • 本报告的见解将使负责人和企业经营团队能够就未来的产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
  • 全球药物和基因输送设备市场报告迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进入者和金融分析师。
  • 相关人员将透过全球药物和基因输送设备市场分析中使用的各种策略矩阵来做出决策。

目录

第一章 调查目的与前提条件

  • 研究目标
  • 先决条件
  • 简称

第二章 市场展望

  • 报告描述
    • 市场定义和范围
  • 执行摘要
  • 一致的机会图（COM）

第三章市场动态、法规与趋势分析

  • 市场动态
    • 全球慢性病负担日益加重
    • 严格的规章制度
    • 药物和基因输送装置的需求不断增加
  • 影响分析
  • 监管情景
  • 产品发布/核准
  • PEST分析
  • 波特分析
  • 併购场景

第四章全球药物与基因传递设备市场-冠状病毒（COVID-19）大流行的影响

  • COVID-19流行病学
  • 供需侧分析
  • 经济影响

5. 全球药物和基因递送设备市场（按产品划分），2020 年至 2032 年

  • 介绍
  • 视网膜下注射套管
  • 延长管
  • 静脉导管
  • 无菌胰岛素注射器
  • 预填充式注射器
  • 点滴袋

6. 全球药物和基因递送设备市场（按非处方药划分），2020 年至 2032 年

  • 介绍
  • Luxturna
  • Yescarta
  • 佐尔根斯玛
  • 基姆里亚
  • Provenge
  • 斯特里姆贝里斯

7. 2020 年至 2032 年全球药物与基因传递设备市场（按地区）

  • 介绍
  • 北美洲
  • 拉丁美洲
  • 欧洲
  • 亚太地区
  • 中东
  • 非洲

第八章 竞争态势

  • Pfizer, Inc.
  • Novartis AG
  • Kite Pharma, Inc.
  • Bluebird bio, Inc.
  • Vericel Corporation
  • uniQure NV
  • Spark Therapeutics, Inc.
  • Renova Therapeutics
  • Orchard Therapeutics plc
  • Kolon Tissue Gene, Inc.
  • Human Stem Cell Institute
  • Amgen, Inc.
  • Dendreon Pharmaceuticals
  • Helixmith Co.
  • Bausch & Lomb Incorporated, Ltd.（ViroMed Co., Ltd.）
  • Becton Dickinson and Company
  • Castle Creek Biosciences, Inc.（Fibrocell Technologies, Inc.）

第九章 章节

  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI5864

Drug and Gene Delivery Devices Market is estimated to be valued at USD 210.8 Thousand in 2025 and is expected to reach USD 454.5 Thousand by 2032, growing at a compound annual growth rate (CAGR) of 11.6% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 210.8 Thousand
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 11.60% 2032 Value Projection: USD 454.5 Thousand

The field of drug and gene delivery involves the development and delivery of drugs, genes, and/or gene products that ultimately alter protein expression and function of the cells, tissues, and living organisms. Drug delivery devices are the tools used to deliver the drug through the specific route of administration. While, gene delivery is the process of introducing foreign genetic material, such as DNA or RNA, into host cells.

Market Dynamics:

Rise in burden of chronic diseases, such as infectious disease, cardiovascular disease, cancer, and diabetes, increasing demand for drug or gene delivery devices, increasing funding for cell and gene therapies, and rise in approvals for gene therapies are major factors expected to augment the growth of the global drug and gene delivery devices market over the forecast period.

For instance, in November 2022, Imunon, Inc. and Acuitas Therapeutics signed an agreement to evaluate the combination of IMUNON's PLACCINE nucleic acid vaccine constructs formulated with Acuitas' proprietary lipid delivery technology. Under the agreement, IMUNON will evaluate administration of its vector constructs formulated in various Acuitas LNP formulations for gene expression and immunogenicity in murine models.

Key features of the study:

  • This report provides in-depth analysis of the global drug and gene delivery devices market, and provides market size (US$ Thousand) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global drug and gene delivery devices market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Pfizer, Inc., Novartis AG, Kite Pharma, Inc., Bluebird bio, Inc., Becton, Amgen, Inc., Vericel Corporation, uniQure N.V., Spark Therapeutics, Inc., Renova Therapeutics, Orchard Therapeutics plc, Kolon Tissue Gene, Inc., Human Stem Cell Institute, Dendreon Pharmaceuticals, Dickinson and Company, Helixmith Co., Ltd (ViroMed Co., Ltd), Bausch & Lomb Incorporated, and Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.), among others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global drug and gene delivery devices market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global drug and gene delivery devices market.

Detailed Segmentation:

  • Global Drug and Gene Delivery Devices Market, By Product:
    • Sub-retinal Injection Cannula
    • Extension Tube
    • Intravenous Catheter
    • Sterile Insulin Syringe
    • Pre-filled Syringe
    • Infusion Bags
  • Global Drug and Gene Delivery Devices Market, By Commercialized Drugs:
    • Luxturna (Drug Delivery Devices)
    • Yescarta (Drug Delivery Devices)
    • Zolgensma (Drug Delivery Devices)
    • Kymriah (Drug Delivery Devices)
    • Provenge (Drug Delivery Devices)
    • Strimvelis (Drug Delivery Devices)
  • Global Drug and Gene Delivery Devices Market, By Region:
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
  • Company Profiles:
    • Pfizer, Inc.
    • Novartis AG
    • Kite Pharma, Inc.
    • Bluebird bio, Inc.
    • Becton Dickinson and Company
    • Amgen, Inc.
    • Vericel Corporation
    • uniQure N.V.
    • Spark Therapeutics, Inc.
    • Renova Therapeutics
    • Orchard Therapeutics plc
    • Kolon Tissue Gene, Inc.
    • Human Stem Cell Institute
    • Dendreon Pharmaceuticals
    • Helixmith Co., Ltd (ViroMed Co., Ltd.)
    • Bausch & Lomb Incorporated
    • Castle Creek Biosciences, Inc. (Fibrocell Technologies, Inc.)

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Product
    • Market Snapshot, By Commercialized Drugs
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Rise in burden of chronic diseases across the globe
    • Stringent rules and regulations
    • Increasing demand for drug and gene delivery devices
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Drug and Gene Delivery Devices Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Drug and Gene Delivery Devices Market, By Product, 2020-2032, (US$ Thousand)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021-2032
    • Segment Trends
  • Sub-retinal Injection Cannula
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Thousand)
  • Extension Tube
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Thousand)
  • Intravenous Catheter
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Thousand)
  • Sterile Insulin Syringe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Thousand)
  • Pre-filled Syringe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Thousand)
  • Infusion Bags
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Thousand)

6. Global Drug and Gene Delivery Devices Market, By Commercialized Drugs, 2020-2032, (US$ Thousand)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021-2032
    • Segment Trends
  • Luxturna (Drug Delivery Devices)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Thousand)
  • Yescarta (Drug Delivery Devices)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Thousand)
  • Zolgensma (Drug Delivery Devices)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Thousand)
  • Kymriah (Drug Delivery Devices)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Thousand)
  • Provenge (Drug Delivery Devices)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Thousand)
  • Strimvelis (Drug Delivery Devices)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Thousand)

7. Global Drug and Gene Delivery Devices Market, By Region, 2020-2032, (US$ Thousand)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021-2032
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Thousand)
    • Market Size and Forecast, and Y-o-Y Growth, By Commercialized Drugs, 2020-2032,(US$ Thousand)
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Thousand)
    • Market Size and Forecast, and Y-o-Y Growth, By Commercialized Drugs, 2020-2032,(US$ Thousand)
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Thousand)
    • Market Size and Forecast, and Y-o-Y Growth, By Commercialized Drugs, 2020-2032,(US$ Thousand)
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Thousand)
    • Market Size and Forecast, and Y-o-Y Growth, By Commercialized Drugs, 2020-2032,(US$ Thousand)
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Thousand)
    • Market Size and Forecast, and Y-o-Y Growth, By Commercialized Drugs, 2020-2032,(US$ Thousand)
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Thousand)
    • Market Size and Forecast, and Y-o-Y Growth, By Commercialized Drugs, 2020-2032,(US$ Thousand)

8. Competitive Landscape

  • Pfizer, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Kite Pharma, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bluebird bio, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Vericel Corporation
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • uniQure N.V.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Spark Therapeutics, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Renova Therapeutics
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Orchard Therapeutics plc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Kolon Tissue Gene, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Human Stem Cell Institute
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Amgen, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Dendreon Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Helixmith Co.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bausch & Lomb Incorporated, Ltd. (ViroMed Co., Ltd.)
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Becton Dickinson and Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Castle Creek Biosciences, Inc. (Fibrocell Technologies, Inc.)
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Analyst Views

9. Section

  • Research Methodology
  • About us